Alethio Therapeutics Email Format

Pharmaceutical ManufacturingEngland, United Kingdom11-50 Employees

Alethio Therapeutics is a pharmaceutical company focused on myeloproliferative neoplasms, pursuing disease-modifying therapies intended to improve patient outcomes. Its work centers on developing novel treatments for these hematologic conditions, prioritizing approaches that address the underlying disease biology rather than simply alleviating symptoms. The company is based in Abingdon, England, and operates with a relatively small team.

In April 2026, Alethio Therapeutics announced the unveiling of ATX-011, a first-in-class antibody described as mutation-agnostic for use in essential thrombocythemia, a form of MPN. This development represents a concrete step in advancing targeted, disease-modifying options within its niche. The company positions itself within the pharmaceutical manufacturing sector by pursuing therapies for myeloproliferative neoplasms from its UK base, with the aim of offering new treatment avenues to affected patients.

Sign up for free to view info

Company overview Employee directory